icon

Monday proved to be a ho-hum day for the broad markets, with not much excitements as the major markers trading slightly in the red for the duration of trading. There were, however, some stocks on the move making noise while a few nice volume plays were worth noting because, as they say, many times volume precedes price...

Premier Alliance Group (PIMO) was a stock to watch last week as trading volume started to pick up, and that volume boost carried into the new trading week, too, as PIMO shares traded on well more than triple the daily average to open the new trading week. As previously discussed, Premier has been growing its customer base over the past few years and increasing its revenues and earnings, as well, all while completing some key acquisitions and mergers that have thrust the company into the heart of one of the most rapidly growing sectors - energy efficiency and devising methods and programs to maximize that efficiency...

Read more

Shares of Cel-Sci Corp (CVM) were up by roughly eight percent for most of the day on Monday, with no news being released in conjunction with the price rise and not much more than the average volume trading throughout the day. Cel-Sci did receive mention on a couple of popular news and finance related websites, however, as Fox Business and Forbes.com noted the gap up and early price action of the company's stock and highlighted the performance as one of the best in biotech.

Another recent high-flyer made the Forbes report as well, as shares of Synergy Pharmaceuticals (SGYP) opened the week with a fourteen percent price spike...

Read more

At the conclusion of each week,VFC's Stock House examines some news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well. Although focusing intently on the biotech and healthcare sectors, due attention is also given to potential market-moving or game-changing companies in a broad variety of sectors and industries. The 'Weekly Stock Watch' will also introduce new companies for coverage and identify some stocks that may have entered 'buy territory'.

Another strong week was recognized by the markets, with a slew of positive earnings reports boosting stocks higher every day and into the close on Friday.

The most notable report may have come fromApple (AAPL). Although AAPL shares had slipped over theprevious weeks, another strong round of earnings that again confirmed the company's dominance in the tech arena quickly sent shares back to over the six hundred dollar mark....

Read more

Synergy Pharmaceuticals (SGYP), a company developing a potential billion-dollar drug, Plecanatide, according to numerous analyst predictions, may have received quite a boost on the news front at the open of this new trading week.

Ironwood Pharmaceuticals (IRWD) and partner Forest Laboratories, Inc. (FRX) informed investors on Monday that the FDA will take an additional three months to review data for Linaclotide, which is before the FDA for review in the indications of chronic idiopathic constipation (CIC) and constipation-predominant irritable bowel syndrome (IBS-C)...

Read more

Although trading near its 52-week high these days, and boasting a significant cash influx through the sale of its non-core businesses, Pfizer Inc. (PFE) still has the task ahead of rebuilding the company's drug development program with a slew of big-name drugs coming off label, including the blockbuster Lipitor that lost its patent protection last year.

Although it's been mentioned that Pfizer will initiate some share buybacks and utilize the new found spare cash to boost investor value in other ways, it's fair to speculate that the pharmaceutical powerhouse might look to complete a key acquisition or two - and the season for such a move is ripe...

Read more

As the buyout offers for new technologies and drugs heats up in the pharmaceutical and biotech sectors, it's the patent games - which have turned into all-out legal wars at times, that are heating up in the tech sector. While Facebook (FB) and Yahoo! (YHOO) took to the courtrooms to battle over patents, Microsoft (MSFT) and AOL (AOL) played nice and secured a billion dollar patent deal earlier this month, which now looks to have been just a preparatory move before negotiating a three team trade.

Read more

Last week we wondered whether or not shares of Keryx Pharmaceuticals (KERX) were heading for the dollar mark. This week it's a whole new ballgame as a Monday morning press release issued by Keryx informed investors that Japanese partner, Japan Tobacco Inc. (JT) and Torii Pharmaceutical Co., Ltd. (Torii), had announced positive top line results of a Phase III trial for Zerenex in the treatment of hyperphosphatemia in end-stage renal disease patients on hemodialysis.

As a result of the news KERX shares were up by more than 25% on volume of well more than double the daily norm - all before lunch time on Monday...

Read more

At the conclusion of each week, VFC's Stock House examines some news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well. Although focusing intently on the biotech and healthcare sectors, due attention is also given to potential market-moving or game-changing companies in a broad variety of sectors and industries. The 'Weekly Stock Watch' will also introduce new companies for coverage and identify some stocks that may have entered 'buy territory'.

Some solid earnings reports last week by a few key players made for an overall decent week for the markets last week, and with earnings again set to dominate the scene during the coming week, it's likely that the markets will once again follow the results.

On the heels of a strong earnings report and more than double the average volume, shares ofMicrosoft (MSFT)soared by nearly five percent on Friday and have positioned the stock as one to watch during the coming week following the exciting close of Friday...

Read more

Thursday afternoon VFC's Stock House informed readers that Capstone Turbine (CPST) had issued a press release stating that the company's President and CEO, Mr. Darren Jamison, would appear for a brief a segment on CNBC's "Fast Money" after the market close.

Shares of Capstone closed the day up by nine percent, while after-hours trading pushed shares even higher, after the CNBC segment aired.

Mr. Jamison did not announce anything that was not already public knowledge, as expected, but the company was highlighted as one that is able to take well advantage of the current low prices of gas - the fuel of choice to power its low-emission microturbine units...

Read more

Last year shares of Capstone Turbine (CPST) broke through the two dollar mark for a period time, in part due to a boost provided by US President Barak Obama when he gave the company a mention during a speech about energy policy in Brazil. Although CPST has since retreated - and even fell below a buck for a period of time over recent trading sessions - the point was made; this company has the potential to play a key role in the fueling the transition to a green energy future...

Read more

Sometimes the patience pays off.

For months now, if not years, discussions of a possible GlaxoSmithKline (GSK) buyout of Human Genome Sciences (HGSI) have been discussed among the speculative - and sometimes not so speculative - circles, given that the two companies were essentially married already through a partnership deal for Benlysta, Human Genome's lupus-treating drug that became the first such treatment approved by the FDA in over fifty years.

Read more

After opening this week on a lackluster trading volume note, shares of Premier Alliance Group (PIMO) saw a bit more action on Wednesday with over 17,000 shares trading hands - about a third higher than the norm. As discussed earlier in the week, Premier is primed to take advantage of the growing regulation from state and federal governments regarding energy consumption. The company has already banked multiple clients in Southern California related to finding energy efficiencies, tax incentives and cost savings for companies and local governments through its GreenHouse division, a recognized expert in the region for its energy-related advisory and consulting services...

Read more

Shares of Immunocellular Therapeutics (IMUC) have been on the fly since the opening days of 2012, even having tripled at one point before settling down to a trading range of just below the three dollar mark.

With numerous catalysts still pending this year, including a possible move to the AMEX and the presentation of interim results for the ongoing ICT-107 trial - which could come as early as late 2012 - this is still a company and a stock to watch...

Read more

The dust has settled, the skies have cleared and the skies have calmed - at least for now.

When Kerxy Pharmaceuticals (KERX) announced earlier this month that Phase III trials failed for its lead cancer-fighting product, Perifisone, it brought a stark reminder and a swift dose of reality to investors of the biotech and small pharmaceutical sector who can often make out like bandits by riding the waves, but can just as easily see the paper gains disappear by holding on for just a little bit too long...

Read more

It's been a nice week for the rebounding markets. Here's a few stocks to watch as the week goes on...

Immunocellular Therapeutics (IMUC): Shares of Immunocellular Therapeutics (IMUC) have been on the fly since the opening days of 2012, even having tripled at one point before settling down to a trading range of just below the three dollar mark.

With numerous catalysts still pending this year, including a possible move to the AMEX and the presentation of interim results for the ongoing ICT-107 trial - which could come as early as late 2012 - this is still a company and a stock to watch.

According to a PR from the company released a couple of months ago, full enrollment for the trial is expected to reached within the current quarter and an interim analysis will be conducted "when 50% of events (32 deaths) have been observed."

Read more

Synergy Pharmaceuticals (SGYP) has numerous catalysts pending for the remainder of 2012 and could be gearing up to make a splash in the healthcare and pharmaceutical sectors as those catalysts unfold. Proof positive may be the fact that - within just the past month - three analysts have issued enthusiastic 'Buy' ratings on the company, with each posting price targets of well more than double that of where SGYP trades today.

Summer Street initiated coverage with a price target of $9, Brean Murray's rating was accompanied by a price tag of $13, and just a couple of weeks ago Roth Capital threw its own prediction into the mix with a target of $12.

As of Tuesday afternoon, SGYP was trading for just a tad above the four dollar mark on below average volume, so what are the analysts seeing right now that investors have not yet caught on to?

Read more

Building on the solid growth momentum established through internal expansion and with the inking of some key mergers and acquisitions over the past few quarters, Premier Alliance Group (PIMO) is a company positioned to make a significant move in the consulting, advisory and energy sustainability markets at a time when increased regulation from Washington and local municipalities is providing a boost for firms working in Premier's arena.

Most notably, the company acquired GreenHouse Holdings last month in a move that pushes Premier head-first into the energy and sustainability sector that is quickly growing into a multi-billion dollar market of its own. Businesses of all sizes, including most municipal, state and federal agencies, are consistently looking for means and methods to trim their energy costs while also meeting the stringent environmental standards being imposed by the environmental branches of the federal government in today's age...

Read more

With the market expected to continue on its southward journey this week, it might be worth keeping an eye on Human Genome Sciences (HGSI) as a potential 'rebound buy' to hang onto until after the market settles and the downward momentum is eased.

HGSI shares traded down by over three percent on Friday, although volume was relatively light when compared to the daily norm. The market as a whole was heading lower, too, so many speculative plays such as HGSI were also heading lower and will continue to be vulnerable to accentuated price drops as long as big money is rolling out of the market, and not in...

Read more

At the conclusion of each week, VFC's Stock House examines some news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well. Although focusing intently on the biotech and healthcare sectors, due attention is also given to potential market-moving or game-changing companies in a broad variety of sectors and industries. The 'Weekly Stock Watch' will also introduce new companies for coverage and identify some stocks that may have entered 'buy territory'.

Last week was one that belonged to the traders, with quite a bit of downwards action in the markets peppered with a couple of big up days, too. Friday's fall, however - when the DOW dropped over one hundred and thirty points - could have set the tone for Monday's open.

In today's age of volatility, quick-breaking news and intense media hype all playing on the markets, we never really know what's coming next until we get there - which makes it a great trading environment, and also allows those who like to hold for the long term to average down on quite a few instances...

Read more

Mets fans, it was a heck of a four game stretch. Now it's time for us to start looking forward to spring training next year.

The markets halted a five day skid on Wednesday, and early indicators are that Thursday could bring some additional rebound. It's my opinion that we haven't seen the last of the downswing, that the declines of today's era will be more slow and gradual than the falling-off-the-cliff phenomena of years past that attracted too much regulator and political attention than Wall Street liked.

But at the end of the day, I'm just a guy with an opinion, so we'll see how it plays out.

Here's a brief recap of some stories and events from the markets over the past twenty-four hours...

Read more

With the Facebook (FB) IPO quickly approaching on the horizon you'd think that all attention in Cyberworld would be focused on that historic event, which is being touted as the biggest IPO in its sector since Google (GOOG) stormed onto the scene years ago. Unfortunately for those that are monitoring this key situation as a pivot point for the exponential growth of Facebook's online dominance, some sideshows are playing out that are hardly irrelevant and are stealing some of the thunder from the main event, which is the Facebook IPO...

Read more

Biovest International (BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (ABPI), announced on Tuesday that the company will file with the Canadian health authorities for the approval of BiovaxID for the treatment of follicular non-Hodgkin’s lymphoma, an incurable cancer of the immune system.

The filing in Canada is part of an international strategy for seeking marketing approvals, which includes the planned filing with the US FDA later this year, and also follows a formal pre-filing advisory meeting with Health Canada's Biologics and Genetic Therapies Directorate (BGTD).

According to comments made in a Tuesday press release, discussions with the BGTD regarding the BiovaxID submission for approval ...

Read more

With a market downturn currently in effect, at least by the looks of it since the new quarter started, we'll take a look at some companies that may be able to buck the trend and outperform the markets over the short term. Tuesday morning we presented Immunocellular Therapeutics (IMUC) as one such company and now we bring you an update on Implant Sciences (IMSC).

In Tuesday morning's stock market roundup it was noted that growing volume in shares of Implant Sciences had finally materialized into a significant stock move, with shares closing the day Monday twenty percent higher than the previous close.

High volume continued into the open on Tuesday and IMSC's new found $1 share price held steady through mid-day trading.

Read more

With a new trading quarter upon us, the broad markets as a whole look ready to take a downswing after a strong first quarter and months of running higher as the global economy demonstrated a strength and resiliency not seen for years. Although a downswing - or "correction", as some might term it - could be in the works, there are some companies and stocks out there with enough pending news, catalysts and developments that may allow them to weather the storm and outperform the near-term market trends.

Immunocellular Therapeutics (IMUC) is one that has already well-outperformed the market this year and could maintain strength into any general downswing...

Read more

The DOW started the new trading week on a down note, trading lower for the fourth trading day in a row and settling in at below the 13,000 mark. News headlines have gone negative on the hopes of continued economic momentum, as predicted, with both sides of the political spectrum playing up the March jobs report to benefit their own respective interests.

This week we'll take a look at some falling stocks that may trade down with the market for the time being, but could quickly rebound when the downward momentum is finished thanks to expectations of solid news developments or pending catalysts that could help reverse the trend.

With the market dipping, there were also some solid new bytes hitting the wires. We'll also take a look at some companies that may be bucking the downward trend and moving higher based on key developments...

Read more

Over the past few months Ampio Pharmaceuticals (AMPE) has issued positive updates regarding all of its pipeline fronts, and as a result shares temporarily returned to the four dollar mark before subsiding back to the south of $3.50.

The most recent news update came last week when it was announced that Ampio would move forward with plans to seek an approval for Zertane in Australia. Zertane is a treatment for premature ejaculation for which the company is seeking regional partners globally to bring the product to market. One such deal was announced last year. Newly-signed commercial partner Daewoong Pharmaceuticals Co. Ltd will market the product in South Korea - and seek to combine it with another sexual dysfunction drug - while an update from Brazil last month revealed that FBM Industria Farmaceutica Ltda will look to bring Zertane to market in that country...

Read more

Shares of Spectrum Pharmaceuticals (SPPI) were dropping fast late last week, with Thursday's trading day culminating in a near-ten percent price dip after the company announced that apaziquone - a late-stage treatment for bladder cancer for which the company planned to file for approval later this year - failed to meet individual Phase III trial endpoints. According to a company press release, however, pooled data from the trials looked to show efficacy, compelling the company to discuss bringing that information before the FDA for a look-see before moving forward, but there's little hope that the FDA would approve on the pooled data alone...

Read more

At the conclusion of each week, VFC's Stock House examines some news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well. Although focusing intently on the biotech and healthcare sectors, due attention is also given to potential market-moving or game-changing companies in a broad variety of markets and industries. The 'Weekly Stock Watch' will also introduce new companies for coverage and identify some stocks that may have entered 'buy territory'.

The first trading week of the new quarter is in the books, and while the DOW stood firm above the 13,000 mark last week, a quick scan of the headlines shows us that sentiment has quickly turned towards expectations of a broad market downturn...

Read more

"Readers Respond" is a forum where readers run the show by commenting or adding to ongoing discussions regarding events or companies that have either been covered by VFC's Stock House or are worth bringing to the attention of readers. Remember, you don't have to agree with VFC to contribute - the best discussions are the ones where all angles are covered. All comments are welcome via email: vfc@vfcsstockhouse.com, Twitter (@VFCsStockHouse), Facebook or the VFC's Stock House Seeking Alpha page.

From kb5233 in response to Thursday's 'Stock Market Roundup' which highlighted Ampio Pharmaceuticals (AMPE), a company that was the target of a harsh review by TheStreet.com's biotech blog that morning:

What is your opinion on the "biotech blogger's" comments on CVM? He has written some previous articles that outline a number of, if not falsehoods, what appears to be some questionable data. Thanks.

Read more

Ampio Pharmaceuticals (AMPE): TheStreet.com's biotech blogger graced readers with an early edition of the Biotech Stock Mailbag this week, releasing it on Thursday vice its normal Friday publishing. In this week's edition he criticized Ampio Pharmaceuticals for taking its treatment for premature ejaculation (PE), Zertane, overseas. Ampio has been seeking regional partners to commercialize Zertane, with one agreement being announced last year to bring the product to market in South Korea, and another commercialization plan announced for Brazil last month.

Ampio then announced in report from earlier this week that the company would next seek an approval for the product in Australia.

Read more

Carrying a heavy short interest of nearly 20% and the move towards profitability still a little bit of ways away, shares of Capstone Turbine (CPST) have been beaten back to the dollar level, a place where recent history has proven to be a decent buy-in level. At times shares have briefly dipped below the dollar mark, but rebounded in fairly quick fashion. Last year, in fact, shares even breached the two dollar level after a mention by US President Barak Obama during an energy speech in Brazil.

Still, as the world turns towards greener energy alternatives, Capstone is positioned to take advantage of that trend...

Read more

Some news, notes and stories wrapping-up Tuesday and trending towards Wednesday...

Weak Moves of the Week:

These events may or may not have occurred this week, but they've been identified as 'weak' this week...

President Barak Obama: Attempting to intimidate members of the Supreme Court and questioning their powers was a weak move by the President. His argument for doing so was even weaker. The people may not have elected the Justices, but the people didn't have a vote on the health care bill either...

Read more

A roundup of news to watch for Tuesday's trading...

Illumina Inc. (ILMN): Volume has been impressive for Illumina (ILMN) over the past few trading days after Illumina's board rejected a buyout offer from Roche Holding AG (RHHBY) for $51 per share. The rejection was unanimous and followed a previous offer of $44.50 per share, a far cry from where ILMN shares traded late last year after an earnings miss sent them tumbling.

The bid is a hostile one, meaning it was unsolicited, but it looks like Illumina intends to stand firm.

Read more

In continuing with the swift progress that Ampio Pharmaceuticals (AMPE) has been making on all pipeline fronts over the past months, the company announced this week that it has reached an agreement with the Therapeutic Goods Administration, Canberra, Australia, on a plan of drug manufacture and quality control for Zertane.

Zertane is a treatment for premature ejaculation (PE) for which Ampio is seeking regional partners to commercialize. An agreement was announced last year to bring the product to market in South Korea, and a similar commercialization plan for Brazil was announced last month...

Read more

It may have been a rough day for Keryx Biopharmaceuticals (KERX) on Monday after a late stage trial for the cancer drug Perifisone didn't quite pan out, but it was a money day for Agenus, Inc. (AGEN) investors after the company announced that it would be presenting some positive trial data of its own at an upcoming conference.

Monday's announcement highlighted and followed-up on data presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting which showed that 93% of the patients from a Phase II Prophage trial were alive at the 26 week mark after surgery with a median overall survival of 11 months.

Progphage is AGEN's developmental stage immunotherapeutic cancer treatment for glioma...

Read more

With great reward, comes great risk, and vice-versa, especially in the biotech/small pharma sector.

For months Keryx Biopharmaceuticals (KERX) was drawing increased investor attention, and as is usually the case in this sector, much of it was speculative attention based on pending results from a Phase III trial for Perifisone, which Keryx in-licensed from Aeterna Zentaris (AEZS) as a potential first-in-class oral anti-cancer drug.

The rewards came along with all the attention...

Read more

Given the company's fall from grace and the potential for investors to view its share price drop as a potential rebound play, Research In Motion (RIMM) is going to be a hot stock to watch for quite a while. Investors looking for a quick turnaround, however, were disappointed last week when losses of over $100 million sent many of RIM's board members running for the doors as the company opened up a new strategy of appealing to its enterprise business while - at least for the time being - not trying to compete with Apple's (AAPL) iPhone or Google's (GOOG) Android on the consumer market...

Read more

Last year was a pivotal year for Coronado Biosciences (CNDO), and with multiple pipeline catalysts set to evolve over the coming months, 2012 is taking shape as a milestone year as well.

Coronado began 2011 as a private company, and after a brief period of trading on the OTC market, the company ended the year on the Nasdaq - without having conducted an IPO. A Form 10 filing with the SEC to convert the company's shares to common stock and become a public company was an unorthodox method of going public, but it did the trick. The quick move to the Nasdaq also ensured that Coronado could appeal to a wider scope of potential investors, as many funds and institutions will not touch a bulletin board stock, and neither will the more conservative of investors.

That said, trading on the Nasdaq also brings with it a responsibility to demonstrate a strength in the pipeline that would compel investors to buy in, and then to stick around as that pipeline developed. Investors will often find themselves asking, "What makes this pipeline or product unique, and what is the potential return should it (they) make it to market?"

Read more